BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Bioventus LLC, Pfizer deal

Bioventus acquired an exclusive, worldwide license to Pfizer's bone morphogenetic protein (BMP) portfolio and associated IP. The portfolio includes a next-generation BMP in preclinical development and rights to recombinant human BMP 2 (rhBMP-2) in undisclosed indications previously reserved to Pfizer. Bioventus also acquired an exclusive option to a BMP program for...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >